16% 1st-qtr 2006 sales rise for Schering AG
In first-quarter 2006, German drugmaker Schering AG achieved net sales of 1.41 billion euros ($1.73 billion), up 16% on the like period of the previous year.
The firm's healthy set of preliminary revenue figures were mainly driven by the multiple sclerosis drug Betaferon/Betaseron (interferon beta-1b), which rose 23% to gross 232.0 million euros, and its contraceptive Yasmin (drospirenone/ethinyl estradiol), which leapt 34% to 180.0 million euros.
The Berlin-headquartered firm says that, once its figures are audited, it anticipates an operating profit for the period of 240.0 million euros, up 4%, noting that, without adjusting for one-time effects relating to divestitures and takeover offers, the operating profit would have amounted to 280.0 million euros, a 22% rise. It says it expects to see profits up 21% to 174.0 million euros, which corresponds to a 21% increase in earnings per share of 0.92 euro.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze